You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Ibritumomab tiuxetan - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for ibritumomab tiuxetan
Recent Clinical Trials for ibritumomab tiuxetan

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
Joseph TuscanoPhase 2
University of California, DavisPhase 2

See all ibritumomab tiuxetan clinical trials

Recent Litigation for ibritumomab tiuxetan

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11
AbbVie Inc. v. Alvotech hf.2021-04-27

See all ibritumomab tiuxetan litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all ibritumomab tiuxetan litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ibritumomab tiuxetan Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ibritumomab tiuxetan Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 ⤷  Sign Up 2015-04-07 Company disclosures
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 ⤷  Sign Up 2015-07-07 Company disclosures
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 ⤷  Sign Up 2015-12-01 Company disclosures
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 ⤷  Sign Up 2039-03-29 Company disclosures
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 ⤷  Sign Up 2019-06-04 Company disclosures
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 ⤷  Sign Up 2021-01-27 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for ibritumomab tiuxetan Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for ibritumomab tiuxetan

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122004000036 Germany ⤷  Sign Up PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
2004C/016 Belgium ⤷  Sign Up PRODUCT NAME: IBRITUMOMAB; AUTHORISATION NUMBER AND DATE: EU/1/03/264/001 20040119
CA 2009 00043 Denmark ⤷  Sign Up PRODUCT NAME: RITUXIMAB; NAT. REG. NO/DATE: EU 1/98/067/001-002 19980602; FIRST REG. NO/DATE: CH IKS 54378 01 19971127
91620 Luxembourg ⤷  Sign Up 91620, EXPIRES: 20181112
91089 Luxembourg ⤷  Sign Up 91089, EXPIRES: 20181112
122009000070 Germany ⤷  Sign Up PRODUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: EU/1/98/067/001-002 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.